Navigation Links
Sorrento Therapeutics Awarded NIH Grant for MRSA Program

SAN DIEGO, May 21 /PRNewswire-FirstCall/ -- Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus (S. aureus or "Staph") infections, including methicillin-resistant S. aureus (MRSA), by disrupting quorum sensing, a bacterial communication process essential to virulence. The Phase I grant is for $300,000 annually for two years, with the possibility of Phase II funding of $1 million per year for up to 3 years.

"It is clear that the NIH is highly motivated to fund novel approaches to tackling the serious healthcare burden of MRSA. We believe our program to develop potential vaccines and antibody therapeutics against MRSA holds great clinical promise because of the high morbidity and mortality caused by this pathogen and the limited treatment options available today," said Antonius Schuh, Ph.D., Chairman and Chief Executive Officer of Sorrento Therapeutics.

Sorrento Therapeutics' MRSA program targets specific auto-inducing peptides (AIPs) central to the quorum sensing system of S. aureus, which induces bacterial virulence. Masking these AIPs leads to a disruption of bacterial communication ("quorum quenching") and suppresses virulence. In recommending the grant application for funding, expert panel reviewers noted that targeting quorum sensing and the virulence factors of S. aureus represented a paradigm shift, which could result in fewer side effects than conventional drug therapies. They also cited the high quality of the investigational team and the impressive preliminary data supporting the program to date. In January, the Company obtained an exclusive license to The Scripps Research Institute's quorum quenching technology, which lays the scientific foundation for this program.

"We believe that the use of quorum sensing signal molecules as targets for the development of vaccines and antibody therapeutics using our proprietary technology platform is a novel and promising approach to combat a serious public health issue. We look forward to working with our colleagues at The Scripps Research Institute and Montana State University in developing novel antibody therapeutics and vaccines against MRSA," said Charlie Rodi, Ph.D., Vice President of Research and Development at Sorrento Therapeutics and the Principal Investigator on the grant.

For 2005, the Centers for Disease Control and Prevention estimated that 94,000 serious invasive MRSA infections occurred in the U.S. and more than 19,000 Americans died from these infections - more than from HIV/AIDS. A recent (2009) study from Duke University Medical Center looking at MRSA infections associated with surgery found a 35-fold increased risk of hospital readmission, a 7-fold increased risk of death, and more than $60,000 of additional charges per patient compared to uninfected controls. IMS Health reported that U.S. sales of antibiotics to treat MRSA exceeded $1 billion in 2007. Although a report from the Government Accounting Office indicates that no federal agency adequately monitors antibiotic resistance or evaluates its social and financial costs, various estimates place the annual cost to the healthcare system as high as $5 billion.

About the Sorrento Therapeutics MRSA Program

Sorrento Therapeutics has obtained an exclusive, worldwide license from The Scripps Research Institute (TSRI) to use this novel quorum sensing technology to identify fully human antibodies for the neutralization of Staph-specific signaling peptides that control bacterial virulence. A research group at the Institute has shown that sequestering these signaling peptides, which are integral components of a bacterial communication process called quorum sensing, results in significantly reduced virulence of MRSA in both cellular and animal models. The Company believes the Staph signaling peptide analogs described by TSRI represent a unique opportunity to develop both vaccines and antibody-based immunotherapeutics to combat MRSA.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. More information is available at Information on the Company's website or any other website does not constitute a part of this press release.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento Therapeutics' MRSA program and its prospects, the research and development opportunities presented by the Company's license agreement with TSRI, Sorrento Therapeutics' potential opportunity to receive funding for the second year of the Phase I grant and a Phase II grant for the MRSA program from the NIH, and the Company's potential development of human vaccines and antibody therapeutics. Risks and uncertainties include whether Sorrento Therapeutics will have sufficient resources to develop vaccines and antibody therapeutics, whether Sorrento Therapeutics will achieve its goals through the license agreement, the term of the license, the Company's ability to collaborate with TSRI and its researchers in the future, whether the Company will seek or gain regulatory approval to market any product candidates in the U.S. or internationally, whether the Company will continue to develop and protect its intellectual property and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Sorrento Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... 2015  Array BioPharma Inc. (Nasdaq: ARRY ... Ron Squarer , will present at the ... The public is welcome to participate in the ... website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, ... p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased ... moderate facial wrinkling. While many patients are aware of the benefits of Botox® in ... delivers to those suffering with discomfort, soreness, and pain as a result of Jaw ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
Breaking Medicine News(10 mins):